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Abstract
Background and Objectives Busulfan is used as part of a
conditioning regimen prior to hematopoietic stem cell
transplantation for the treatment of certain cancers and
immune deficiency syndromes. Due to its instability in
aqueous preparations, busulfan for infusion is prepared
from a concentrate and has a relatively short shelf life once
prepared. The purpose of this study was to identify the
most suitable storage container and temperature to maxi-
mize the shelf life of busulfan therapeutic infusions pre-
pared from Busilvex.
Methods Busilvex 6 mg/mL was diluted to 0.55 mg/mL
with 0.9 % NaCl and aliquots dispensed into polypropyl-
ene syringes, polyvinyl chloride bags, and glass bottles.
Three storage temperatures were evaluated: 2–8 C,
13–15 C (thermostatically controlled chamber), and room
temperature (20 ± 5 C). At set time points, samples were
analysed for busulfan content, using a high-performance
liquid chromatography (HPLC) system with ultraviolet
detection. The change in pH and osmolarity on storage was
also determined, and solutions were inspected visually for
formation of a precipitate or colour change. To determine
the contribution of precipitation to loss of busulfan content
on storage, samples from one time series were treated with
the solvent dimethylacetamide prior to HPLC separation
and quantitation of busulfan.
Results The results of the active substance content mon-
itoring study over a 48-h period demonstrate that busulfan
solution is stable at a 5 % threshold, at 2–8 C for 16 h in
syringes, 14 h in glass bottles, and 6 h in bags. In addition,
the period of stability decreases as the temperature
increases (4 h at 20 ± 5 C). The solution is considered to
be stable, subject to precipitation liable to be observed
regardless of the temperature.
Conclusion The best stability was observed for busulfan
solutions placed at 2–8 C in syringes. This study dem-
onstrated that precipitation, in addition to hydrolysis, has a
significant influence on the busulfan content.
1 Introduction
Busulfan (1,4-butanediol dimethanesulphonate) is an
alkylating agent used extensively for its anti-tumor prop-
erties, characterized in the early 1950s by Galton et al. for
the treatment of chronic myeloid leukemia (CML) [1].
Intravenous busulfan was developed to overcome the
dosing issues associated with the oral form of the drug
(reviewed by Scott et al., 2012 [2]).
Currently, busulfan is indicated for use in conjunction
with other agents for conditioning prior to hematopoietic
stem cell (HSC) transplantation [2, 3]. For adults, it is used
in conjunction with cyclophosphamide (BuCy2 regimen),
whereas for pediatric patients (aged 0–17 years), it can be
used in conjunction with either melphalan (BuMel) or
cyclophosphamide (BuCy4) [2]. These conditioning regi-
mens prior to allogenic or autologous HSC transplantation
are used to treat a large number of malignant diseases such
as leukemia and some solid tumors, as well as genetic
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diseases such as immune deficiency syndromes [4–7].
Other combinations associate busulfan with thiotepa. More
recently, less myoloablative combinations with fludarabine
(BuFlu) have shown efficacy while offering lower extra-
hematological toxicity [8, 9].
According to the Summary of Product Characteristics
(SPC), Busulfan (Busilvex) is administered intravenously
(IV) at a recommended dose of 0.8 mg/kg in adults and
0.8–1.2 mg/kg (depending on bodyweight) in pediatric
patients [3]. It is administered by means of a 2-h infusion
every 6 h for 4 consecutive days (giving a total of 16
doses). Because of its highly predictable linear pharma-
cokinetics, once-daily administrations are under evaluation
in adults [10]. Busulfan is provided as a 6 mg/mL con-
centrate and once it has been reconstituted in the form of a
0.55 mg/mL solution, the stability data provided by Pierre
Fabre Laboratories are 8 h at 20 ± 5 C (room temperature
[RT]) or 12 h at 2–8 C followed by 3 h at RT. More
recently, a German study reported a period of stability of
36 h at a temperature between 13 and 15 C for the same
solutions diluted to a 0.5 mg/mL dose and prepared in
polypropylene (PP) bags or glass bottles [11, 12]. Busulfan
undergoes a hydrolysis phenomenon in aqueous media,
giving rise to methanesulphonic acid and tetrahydrofuran
(THF) [13]. A precipitation phenomenon was also identi-
fied during these studies [11].
The short shelf life specified in the SPC combined with
the administration regimen of every 6 h for 4 consecutive
days poses organizational problems for chemotherapy
preparation, particularly at the end of the week.
The purpose of our study was to investigate the stability
of busulfan injection solution (Busilvex) diluted in 0.9 %
sodium chloride (NaCl) to a concentration of 0.55 mg/mL
(the recommended concentration for administration) in
three different containers: PP syringes, polyvinyl chloride
(PVC) bags, and glass bottles, when stored at three dif-
ferent temperatures (2–8, 13–15, and 20 ± 5 C). We
monitored changes in the busulfan content of this solution,
its pH, and its osmolality over time, and sought to under-
stand the phenomena causing the busulfan content to
decrease.
2 Materials and Methods
2.1 Materials and Reagents
Busulfan (Fig. 1) (Fluka, Steinheim, Germany; purity
C99 %) was used to produce the series of standard solu-
tions for calibration and the quality controls. Diethyldi-
thiocarbamate (Fig. 1) (Sigma-Aldrich, St Louis, MO,
USA) was used to prepare the derivatization solution each
day. The Busilvex used for the preparations was supplied
by Pierre Fabre Oncologie, Boulogne, France. The internal
standard (IS) solutions were prepared with dibromopentane
(Fig. 1) (Aldrich, Steinheim, Germany), diluted in ethanol
(VWR, Fontenay-sous-Bois, France).
The high-performance liquid chromatography (HPLC)
system consisted of a quaternary pump (Merck Hitachi
L7100), an automatic injector (Merck Hitachi L2200), an
ultraviolet (UV) visible detector (Waters 2487), and Multi
HSM Manager software (Merck Hitachi).
The analysis was run using an Agilent Zorbax SB C18
column (5 lm, 150 9 4.6 mm) (Agilent Technologies).
The column was thermostatically controlled at 40 C dur-
ing use and then rinsed with a water (H2O)/methanol (50/
50, v/v) mixture.
Busulfan was detected by absorbance at 281 nm. In
isocratic mode, a mobile phase consisting of acetonitrile
(ACN), H2O, and trifluoroacetic acid (TFA) (proportions:
650/350/1, v/v/v) was run through the system at a flow rate
of 2 mL/min.
2.2 Sample Preparation, Storage, and Processing
Busulfan preparations were produced by diluting the
product Busilvex in 0.9 % NaCl to obtain a final con-
centration of 0.55 mg/mL (therapeutic concentration). The
containers used for the preparations were PP syringes
(Becton Dickinson, Franklin Lakes, NJ, USA; 50 mL, ref:
300865), EasyFlex PVC bags (MacoPharma, Tourcoing,
France) and 250-mL glass bottles containing 0.9 % NaCl
(CDM Lavoisier, Paris, France). Busulfan solutions were
Fig. 1 Chemical structures of a busulfan (1,4-butanediol dim-
ethanesulphonate), b diethyldithiocarbamate, and c dibromopentane
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then aliquoted into smaller containers so that the solutions
remained under the defined storage conditions throughout
the evaluation period. These containers were 3-mL PP
syringes (Becton Dickinson; ref: 300910), 50-mL Easy-
Flex PVC bags (MacoPharma) and 2-mL glass bottles
(Schott, St Gallen, Switzerland; ref: VCDIN2R) of boro-
silicate pharmaceutical type I glass adapted for injections,
fitted with chlorobutyl stoppers.
The storage conditions for each of the containers were
2–8 C, 13–15 C (thermostatically controlled chamber),
and, finally, RT (20 ± 5 C). For each of the conditions
(container and storage temperature), a sample was pro-
cessed and analysed by HPLC-UV either every 6 h or
every 3 h.
Samples were processed in glass tubes because of the
use of dimethylacetamide (DMA). To 0.5 mL of aliquot,
we added 0.5 mL of DMA, followed by 0.1 mL of IS.
After stirring, 1.0 mL of DMA and 0.5 mL of derivatiza-
tion agent were added for a final volume of 2.6 mL. The
solution was stirred a second time before being left to stand
for 1 h at RT, the time required for derivatization prior to
injection. A 30-lL test sample was then injected into the
chromatographic system.
2.3 Transfer and Validation of Method
We adapted the analytical method registered by Pierre
Fabre Laboratories in the marketing authorization appli-
cation. The validation of this method was conducted at our
laboratory according to International Conference on Har-
monisation (ICH) topic Q2R guidelines [14]. We thus
assessed the linearity, precision (i.e. repeatability and
intermediate precision), and accuracy of our method. The
method was shown to be linear over a concentration range
from 0.05 to 0.5 mg/mL.
Under these chromatographic conditions, busulfan and
dibromopentane separated correctly with respective reten-
tion times of 9.6 and 13.3 min (Fig. 2). The chromato-
graphic peak observed at 3.3 min consisted of the unreacted
compound diethyl dithiocarbamate.
2.4 Study Procedure
The stability of busulfan at the therapeutic concentration of
0.55 mg/mL was assessed in the three containers and at the
three temperatures defined above. The assessments were
conducted in two stages: for the first stage, four analyses
were conducted for each series (n = 9) and for time points
of the 48-h period of study (n = 9). For the second one, six
analyses were conducted for each series (n = 9) and for
each time point of the 15-h period of study (n = 6).
2.5 Busulfan Content Monitoring
The first section of the study covered 48 h with one anal-
ysis every 6 h. In order to conduct all of the analyses
during laboratory opening hours, the preparations were
produced in two series with a 6-h interval. For each series,
two preparations were generated for the content analyses
and a further three preparations per container were gener-
ated to assess the loss of mass.
The second section was conducted over a 15-h period. It
consisted of first performing an analysis of the samples
over a shorter period with samples taken every 3 h in order
to determine a more precise period of stability. In addition,
it consisted of investigating the decrease in busulfan con-
tent on storage, so as to understand whether this decrease
was due mainly to busulfan degradation or precipitation.
To do this, we performed a second assay on the same
samples, but after adding DMA to the solution directly in
the container (1:4 dilution of initial sample). After
homogenization, a 2-mL test sample was analysed after
adding 0.1 mL of IS and 0.5 mL of derivatization agent.
DMA is the solvent of choice for busulfan and should
enable the solubilization of any precipitate.
We considered that at time zero (T0), the initial con-
centration (C0) of the active substance was 100 %. The
contents for each analysis time were thus determined on
the basis of C0. According to these conditions, the solu-
tions were considered to be stable if their content was
greater than 90 %, the threshold used by hospital phar-
macists and in the Karstens’ study, or 95 %, the threshold
used by the pharmaceutical industry, such as Pierre Fabre,
of C0.
2.6 Organoleptic Characteristics and Visual Inspection
The stability of the preparations under the various condi-
tions was studied macroscopically by observing whether a
precipitate or crystallization, or a change of colour,
appeared.
2.7 Study of pH and Osmolarity
The pH of each aliquot was measured using a Metrohm 713
pH meter equipped with a Pt 1000 electrode (Metrohm,
Villebon Courtaboeuf, France) after calibration and anal-
ysis of a control solution set at pH 7 prior to each series of
measurements.
For each sample, an osmolarity measurement was made
with a Roebling automatic osmometer (Roebling, Berlin,
Germany) with a prior analysis of a calibration solution set
at 300 mOsm/L.
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3 Results
The busulfan concentration was assessed at the 5 %
threshold, as applied in the Pierre Fabre Laboratories study,
to account for the overall stability of the pharmaceutical
product and at a 10 % threshold to compare our results
with those obtained in a previous study by Karstens and
Kra¨mer [11].
Results of the 48 h series are shown in Fig. 3. When
stored at 2–8 C, dilute busulfan solutions were stable for
longer in PP syringes (i.e. 16 h at a 5 % threshold and 24 h
at a 10 % threshold) than in PVC bags (6 h at a 5 %
threshold and 8 h at a 10 % threshold) or glass bottles
(14 h at a 5 % threshold and 18 h at a 10 % threshold).
Busulfan was more stable when stored at 2–8 C, regard-
less of the container, than at higher temperatures (16 h vs.
8 h at 13–15 C or 4 h at RT based on a 5 % threshold in
syringes, for example).
Results of the 15 h series, with sampling every 3 h, are
shown in Table 1; they confirmed that PP syringes offered
the best stability, regardless of storage temperature.
Macroscopic analysis of the solutions revealed the ran-
dom appearance of a visible precipitate regardless of the
container and the storage temperature.
Regarding the pH of solutions, during the first 12 h of
storage, a reduction of 0.8–1.2 pH units was observed in
solutions prepared in PP syringes compared with 0.9–1.2
units for those prepared in glass and 1.6–1.8 units for those
prepared in PVC bags. The results are presented in Table 2.
This decrease could be explained by the release of me-
thanesulphonic acid that occurs during busulfan degrada-
tion. However, it should be noted that the pH values
measured throughout the study remain compatible with
intravenous administration.
Osmolarity changes (between 0 and 48 h) appear to be
consistent with the stability described above: at 2–8 C,
there is no significant difference in osmolarity, regardless
of the container used; at 13–15 C, osmolarity is signifi-
cantly different in PVC bags (p \ 0.05, p = 0.002) and in
glass bottles (p \ 0.05, p = 0.003). At RT, osmolarity is
significantly different (p \ 0.05; PVC, p = 0.004; PP,
p = 0.04; glass, p = 0.03) regardless of the container used.
In the second part to the study, an analysis was run on the
same samples under the same conditions but after first adding
DMA to solubilize any precipitated busulfan. At each anal-
ysis time and condition, a difference in busulfan content
between the two assays was observed such that the busulfan
content after adding DMA was greater than 90 or 95 % of the
initial concentration. At 12 h, in PVC bags stored at 2–8 C,
the busulfan content was 40.9 %, whereas after adding DMA
the content increased to 85.9 %. In the same conditions, in PP
syringes the content did not differ after adding DMA—
100.3 % before vs. 104.5 % after. This suggested that the
main factor causing the decrease in the busulfan content with
time was indeed the precipitation phenomenon.
4 Discussion
Our study data differ somewhat from other reports on the
stability of busulfan solutions. The divergences observed
between the different studies can be partly explained by
non-identical study conditions and parameters. Indeed,
whereas Pierre Fabre Laboratories who market Busilvex
recommend a shelf-life in PP syringes or in PVC bags of
12 h at 2–8 C followed by 3 h at RT [3], the study by
Karstens and Kra¨mer [11] found a greater period of sta-
bility (19 h) at the same temperature in syringes. Indeed,
the study conducted by the manufacturer made its con-
clusions on the basis of a 5 % threshold, whereas the
German study, conducted in a hospital environment, used a
10 % specification threshold for refrigerated storage only.
Fig. 2 Chromatogram of
busulfan diluted in 0.9 %
sodium chloride at 0.55 mg/mL.
The peak at 9.6 min is busulfan,
and the peak at 13.3 min is
dibromopentane
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Comparing the three containers evaluated in this study,
our results demonstrate that the PP syringe offers the best
storage regardless of temperature. This is in contrast to the
results of the German study, which demonstrated that glass
is more suitable, giving 48 or 36 h of stability depending
on the storage temperature. Senoo and co-workers [15] also
demonstrated that colourless PP syringes offered good
stability for busulfan, with their data indicating that under
refrigeration, busulfan solution was physically and chem-
ically stable for up to 96 h.
Other storage containers are available, including poly-
olefin/polyamide laminate packs. A recent study evaluated
the stability of busulfan solutions when stored in such
packs. Busulfan solutions were prepared in physiological
saline at 0.24 mg/mL and at 0.12 mg/mL and stored under
refrigeration or at RT [16]. Regardless of the drug
Fig. 3 Stability of busulfan
(0.55 mg/mL) diluted in 0.9 %
sodium chloride and stored at
a 2–8 C, b 13–15 C, or
c room temperature
(20 ± 5 C). Busulfan content
was monitored over 48 h (one
analysis every 6 h). Data are
presented as mean ± standard
deviation (n = 8 for T0, n = 4
for other analysis times). PP
polypropylene, PVC polyvinyl
chloride
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concentration or storage conditions, there was less than
90 % of the starting concentration remaining after 24 h.
Another divergence in results relates to the storage
temperature. Whereas the SPC indicates that the period of
stability decreases if the temperature increases, the German
study surprisingly observed stability for up to 36 h at
13–15 C and lower stability, 19 h, at 2–8 C. Our results
indicate that there is a decrease in stability with an increase
in storage temperature; based on a 10 % threshold, stability
in PP syringes was 24 h at 2–8 C, 8 h at 13–15 C, and
8 h at RT. In the study evaluating the polyolefin/polyamide
bags, a lower storage temperature was also associated with
better stability, at least for the 0.24 mg/mL solution (16.7 h
at 4 C vs. 8.4 h at RT) [16]. Interestingly, the stability of
the 0.12 mg/mL solution was largely independent of stor-
age temperature (11.5 h at 4 C vs. 12.0 h at RT).
The second part of our study was an attempt to explain
the reduction in busulfan content on storage. It is well
known that busulfan is only slightly soluble in water, which
justifies the presence of the solvent DMA in the compo-
sition of the pharmaceutical product. In addition, busulfan
is not stable in aqueous media as it undergoes hydrolysis,
producing methanesulphonic acid and tetrahydrofuran.
These two degradation products are not detectable with the
chromatographic method used to assay busulfan. This
hydrolysis will contribute to the decrease in the busulfan
content of preparations over time. However, in this study,
we demonstrated that another phenomenon could be the
main cause of the decrease in the busulfan content, namely
precipitate formation. Precipitation is a phenomenon that is
unpredictable and difficult to control, and a number of
factors may be involved, particularly container/content
interactions as described by Karstens and Kra¨mer [11],
temperature, or agitation. So the explanation could be that
on one hand there is more agitation of PVC bags and glass
bottles than of PP syringes, and on the other hand a higher
temperature can promote interactions between the rough-
ness of the container (especially glass) and the content
responsible for precipitation. Our study enabled a clearer
understanding of this decrease. The initial rapid decline in
busulfan content may be due to precipitation, since treat-
ment of early samples with DMA to dissolve any precipi-
tated busulfan resulted in content levels greater than 95 %
of the starting levels. Hydrolysis appears to be involved in
the subsequent decline in busulfan content.
Reviewing our results, some discrepancies rise, such as
that between the 15- and 48-h series measurements. The
precipitation phenomenon was attributed as the factor that
led to discrepancies, given that the busulfan solution was
assessed and did not include the precipitate (which may
have contained some busulfan). Furthermore, some sam-
ples were precipitated and some were not. When examining
the pH of the solutions, our results demonstrated higher
initial pH values in the PVC bags, and it is thought that this
may have arisen via chemical interaction between DMA
and the material of the bag. Higher initial osmolarity values
were also noted in the PVC bags, which may confirm the
potential pH variations observed in the PVC bags.
5 Conclusions
Of the containers studied, PP was the material allowing the
longest period of stability for busulfan solutions diluted to a
0.55 mg/mL concentration. The longest periods of stability
were obtained for solutions placed at 2–8 C, regardless of
the container. This study allowed us to understand the
decrease of the busulfan content. With hydrolysis degra-
dation, the precipitation phenomen is responsible for
busulfan solutions’ instability. This phenomen affects other






Percentage of initial concentration remaininga
3 h 6 h 9 h 12 h 15 h
PP syringes 4 0.240 ± 0.2 101.5 ± 1.3 100.7 ± 1.3 100.9 ± 1.2 100.3 ± 1.1 100.4 ± 1.0
13 0.238 ± 0.7 100.5 ± 3.2 99.1 ± 2.8 97.4 ± 4.1 94.3 ± 3.4 92.5 ± 4.2
20 0.236 ± 0.9 100.2 ± 3.7 97.1 ± 1.6 95.8 ± 1.5 93.8 ± 1.9 91.7 ± 1.7
PVC bags 4 0.279 ± 0.5 97.9 ± 2.9 90.9 ± 6.2 49.7 ± 8.5 40.9 ± 4.5 14.9 ± 2.5
13 0.230 ± 0.4 97.1 ± 2.1 97.3 ± 2.6 80.8 ± 4.7 65.0 ± 5.8 39.1 ± 5.9
20 0.283 ± 1.4 94.6 ± 5.1 97.0 ± 4.1 91.9 ± 4.3 88.5 ± 6.6 82.4 ± 12.1
Glass bottles 4 0.290 ± 2.7 79.9 ± 6.7 57.3 ± 18.3 45.5 ± 12.3 35.4 ± 19.1 39.1 ± 16.2
13 0.247 ± 0.6 97.6 ± 4.3 87.6 ± 1.3 92.1 ± 14.2 81.8 ± 17.6 70.6 ± 26.2
20 0.261 ± 0.7 85.4 ± 7.4 75.2 ± 9.1 66.7 ± 11.9 59.0 ± 11.7 56.0 ± 10.3
a Values presented as mean ± standard deviation (n = 6)
PP polypropylene, PVC polyvinyl chloride
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drugs such as fungizone, cytarabine (according to the dil-
uent), or etoposide, according to the concentration. For
busulfan, precipitation appears to be temperature related; as
the storage temperature increased, the stability of the dilute
solutions decreased.
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